Actively Recruiting
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
Led by National Cancer Institute, Naples · Updated on 2025-04-01
70
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).
CONDITIONS
Official Title
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of primary hepatocellular carcinoma or other oncological pathology from an accredited medical-clinical facility
- Age 18 years or older
- Ability to provide signed informed consent and comply with study requirements
- For paraffin-embedded samples from pathological anatomy or biological bank, informed consent may not be required per privacy regulations
- Healthy subjects must have no history of tumor or neoplastic pathology treated during their life
- Healthy subjects must be 80 years or older
- Healthy subjects must be able to provide signed informed consent and comply with study requirements
You will not qualify if you...
- Current illnesses requiring antibiotic therapy
- Diagnosis of pre-tumor pathology in healthy subjects
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
Naples, Italy, 80131
Actively Recruiting
Research Team
L
Luigi Buonaguro, DR
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here